A PHASE 2, OPEN LABEL STUDY TO ASSESS AD LIB CONSUMPTION OF PEANUT IN PEANUT ALLERGIC INFANTS 6-THROUGH 12-MONTHS-OLD WITH EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 UG (THRIVE)

Registry ID

V712-205

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

DBV TECHNOLOGIES SA

Start date

2026-05-21

Last update

2026-05-04

Conditions

• ALLERGIES PEANUT

Related clinical trials

• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 ¿G IN 1-THROUGH 3-YEAR OLD CHILDREN WITH PEANUT ALLERGY (COMFORT TODDLERS)
• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 PG IN 4-7- YEAR-OLD CHILDREN WITH PEANUT ALLERGY
• A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF 6-MONTH OF ABATACEPT VS PLACEBO AS ADJUVANT TO PEANUT ORAL IMMUNOTHERAPY TO INDUCE IMMUNOLOGIC CHANGES IN PATIENTS WITH SEVERE PERSISTENT PEANUT ALLERGY (ATARI)
• A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PEDIATRIC PATIENTS WITH PEANUT ALLERGY.
• A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III TRIAL TO ASSESS THE SAFETY AND EFFICACY OF VIASKIN PEANUT IN PEANUT-ALLERGIC YOUNG CHILDREN 1-3 YEARS OF AGE (EPITOPE STUDY)
• REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSION STUDY (RAMSES OLE)

View on source registry